{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:36Z","timestamp":1791919476253,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,3,10]],"date-time":"2013-03-10T00:00:00Z","timestamp":1362873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00228-013-1478-8","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T05:40:19Z","timestamp":1362807619000},"page":"1411-1421","source":"Crossref","is-referenced-by-count":33,"title":["The population pharmacokinetics of allopurinol and oxypurinol in patients with gout"],"prefix":"10.1007","volume":"69","author":[{"given":"Daniel F. B.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R.","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Duffull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas H. G.","family":"Holford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,10]]},"reference":[{"key":"1478_CR1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"},{"key":"1478_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321\u2013325","journal-title":"Arthritis Rheum"},{"key":"1478_CR3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46:623\u2013644","journal-title":"Clin Pharmacokinet"},{"key":"1478_CR4","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 46:1372\u20131374","journal-title":"Rheumatology"},{"key":"1478_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"key":"1478_CR6","unstructured":"US National Library of Medicine DailyMed: FDA information: allopurinol tablet (Zyloprim).Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=13564 . Accessed 15 Aug 2012"},{"key":"1478_CR7","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P (2006) Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 33:1646\u20131650","journal-title":"J Rheumatol"},{"key":"1478_CR8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R (2001) Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 60:981\u2013983","journal-title":"Ann Rheum Dis"},{"key":"1478_CR9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1445-5994.2000.tb00857.x","volume":"30","author":"L Stamp","year":"2000","unstructured":"Stamp L, Gow P, Sharples K, Raill B (2000) The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust NZ J Med 30:567\u2013572","journal-title":"Aust NZ J Med"},{"key":"1478_CR10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","volume":"90","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Barclay ML, O\u2019Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT (2011) Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 90:392\u2013398","journal-title":"Clin Pharmacol Ther"},{"key":"1478_CR11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O\u2019Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412\u2013421","journal-title":"Arthritis Rheum"},{"key":"1478_CR12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","volume":"51","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Barclay ML, O\u2019Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT (2012) Furosemide increases plasma oxypurinol without lowering serum urate\u2014a complex drug interaction: implications for clinical practice. Rheumatology 51:1670\u20131676","journal-title":"Rheumatology"},{"key":"1478_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00292878","volume":"8","author":"SJ Appelbaum","year":"1982","unstructured":"Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D (1982) Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol 8:93\u201398","journal-title":"Cancer Chemother Pharmacol"},{"key":"1478_CR14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00606429","volume":"22","author":"H Breithaupt","year":"1982","unstructured":"Breithaupt H, Tittel M (1982) Kinetics of allopurinol after single intravenous and oral doses: noninteraction with benzobromarone and hydrochlorothiazide. Eur J Clin Pharmacol 22:77\u201384","journal-title":"Eur J Clin Pharmacol"},{"key":"1478_CR15","volume-title":"NONMEM users guide\u2014part VIII.","author":"AJ Boeckmann","year":"2010","unstructured":"Boeckmann AJ, Sheiner LB, Beal SL (2010) NONMEM users guide\u2014part VIII. ICON Development Solutions, Ellicott City"},{"key":"1478_CR16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30:387\u2013404","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1478_CR17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051\u20131065","journal-title":"Clin Pharmacokinet"},{"key":"1478_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25\u201336","journal-title":"Drug Metab Pharmacokinet"},{"key":"1478_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1478_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"1478_CR21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO (2011) Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 38:904\u2013910","journal-title":"J Rheumatol"},{"key":"1478_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","volume":"17","author":"AJ Reyes","year":"2003","unstructured":"Reyes AJ (2003) Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 17:397\u2013414","journal-title":"Cardiovasc Drugs Ther"},{"key":"1478_CR23","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","volume":"344","author":"HK Choi","year":"2012","unstructured":"Choi HK, Soriano LC, Zhang Y, Rodriguez LAG (2012) Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case\u2013control study. BMJ 344:d8190","journal-title":"BMJ"},{"key":"1478_CR24","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2174\/138161205774913309","volume":"11","author":"SS Daskalopoulou","year":"2005","unstructured":"Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005) Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 11:4161\u20134175","journal-title":"Curr Pharm Des"},{"key":"1478_CR25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"J Graessler","year":"2006","unstructured":"Graessler J, Graessler A, Unger S, Kopprasch S, Tausche A-K, Kuhlisch E, Schroeder HE (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292\u2013300","journal-title":"Arthritis Rheum"},{"key":"1478_CR26","doi-asserted-by":"crossref","first-page":"e7729","DOI":"10.1371\/journal.pone.0007729","volume":"4","author":"K Stark","year":"2009","unstructured":"Stark K, Reinhard W, Grassl M, Erdmann J, Schunker H, Illig T, Hengstenberg C (2009) Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 4:e7729","journal-title":"PLoS One"},{"key":"1478_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/hmg\/ddp489","volume":"19","author":"P Harst van der","year":"2010","unstructured":"van der Harst P, Bakker SJL, de Boer RA, Wolffenbuttel BHR, Johnson T, Caulfield MJ, Navis G (2010) Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 19:387\u2013395","journal-title":"Hum Mol Genet"},{"key":"1478_CR28","doi-asserted-by":"crossref","first-page":"e1000504","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M et al (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504","journal-title":"PLoS Genet"},{"key":"1478_CR29","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/art.24938","volume":"60","author":"JE Hollis-Moffatt","year":"2009","unstructured":"Hollis-Moffatt JE, Xu X, Dalbeth N, Merriman ME, Topless R, Waddell C, Gow PJ, Harrison AA, Highton J, Jones PBB, Stamp LK, Merriman TR (2009) Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island, and Caucasian case\u2013control sample sets. Arthritis Rheum 60:3485\u20133492","journal-title":"Arthritis Rheum"},{"key":"1478_CR30","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/ar3816","volume":"14","author":"JE Hollis-Moffatt","year":"2012","unstructured":"Hollis-Moffatt JE, Phipps-Green AJ, Chapman B, Jones GT, van Rij A, Gow PJ, Harrison AA, Highton J, Jones PB, Montgomery GW, Stamp LK, Dalbeth N, Merriman TR (2012) The renal urate transporter SLC17A1 locus: confirmation of association with gout. Arthritis Res 14:R92","journal-title":"Arthritis Res"},{"key":"1478_CR31","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1093\/hmg\/ddq412","volume":"19","author":"AJ Phipps-Green","year":"2010","unstructured":"Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, Merriman ME, Topless R, Gow PJ et al (2010) A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 19:4813\u20134819","journal-title":"Hum Mol Genet"},{"key":"1478_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2036.2010.04349.x","volume":"32","author":"RL Roberts","year":"2010","unstructured":"Roberts RL, Zhang M, Marinaki AM, Stamp LK (2010) Does genetic variability in aldehyde oxidase and molybdenum cofactor sulfurase predict nonresponse to allopurinol? Aliment Pharmacol Ther 32:310\u2013311","journal-title":"Aliment Pharmacol Ther"},{"key":"1478_CR33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2036.2009.04057.x","volume":"30","author":"MA Smith","year":"2009","unstructured":"Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson D (2009) Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 30:375\u2013384","journal-title":"Aliment Pharmacol Ther"},{"key":"1478_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151","journal-title":"AAPS J"},{"key":"1478_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35:401\u2013421","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1478_CR36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","volume":"74","author":"SL Stocker","year":"2012","unstructured":"Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO (2012) The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol 74:477\u2013489","journal-title":"Br J Clin Pharmacol"},{"key":"1478_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1988.tb03401.x","volume":"26","author":"RO Day","year":"1988","unstructured":"Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, Savdie E (1988) Allopurinol dose selection: relationships between dose and plasma oxypuirnol and serum urate concentrations and urinary rate excretion. Br J Clin Pharmacol 26:423\u2013428","journal-title":"Br J Clin Pharmacol"},{"key":"1478_CR38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00315424","volume":"39","author":"GM Peterson","year":"1990","unstructured":"Peterson GM, Boyle RR, Francis HW, Oliver NWJ, Paterson J, von Witt RJ, Taylor GR (1990) Dosage prescribing and plasma oxypurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 39:419\u2013421","journal-title":"Eur J Clin Pharmacol"},{"key":"1478_CR39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2125.1996.03116.x","volume":"41","author":"S Graham","year":"1996","unstructured":"Graham S, Day RO, Wong H, McLachlan AJ, Bergendal L, Minors JO, Birkett DJ (1996) Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 41:299\u2013304","journal-title":"Br J Clin Pharmacol"},{"issue":"6 Suppl","key":"1478_CR40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ard.25.Suppl_6.627","volume":"25","author":"F Delbarre","year":"1966","unstructured":"Delbarre F, Amor B, Auscher C, de Gery A (1966) Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis 25[6 Suppl]:627\u2013633","journal-title":"Ann Rheum Dis"},{"key":"1478_CR41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","volume":"37","author":"Y Ta-F","year":"1964","unstructured":"Ta-F Y, Gutman AB (1964) Effect of allopurinol (4-Hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 37:885\u2013898","journal-title":"Am J Med"},{"key":"1478_CR42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-62-4-639","volume":"62","author":"JR Klinenberg","year":"1965","unstructured":"Klinenberg JR, Goldfinger SE, Seegmiller JE (1965) The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 62:639","journal-title":"Ann Intern Med"},{"key":"1478_CR43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","volume":"64","author":"RW Rundles","year":"1966","unstructured":"Rundles RW, Metz EN, Silberman HR (1966) Allopurinol in the treatment of gout. Ann Intern Med 64:229","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1478-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1478-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1478-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:02Z","timestamp":1558702142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1478-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,10]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1478-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,10]]}}}